Table 2.
Documentation on tumor size and grading could not be procured for all cases due to the retrospective nature of this work. No patients were excluded.
| ACP/PRP | Control (no ACP/PRP) | p value | |||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Patients | 82 | 81 | |||
| Metastatis in SNL | 10 | 12.2 | 14 | 17.3 | 0.3594 |
| Tumor size∗ | |||||
| Tis | 3 | 3.7 | 4 | 4.9 | |
| T1 | 57 | 69.5 | 41 | 50.6 | |
| T2 | 21 | 25.6 | 30 | 37.0 | |
| T3 | 0 | 3 | 3.7 | 0.607 | |
| Grading∗ | |||||
| G1 | 15 | 18.3 | 17 | 21.0 | |
| G2 | 49 | 59.8 | 46 | 56.8 | |
| G3 | 11 | 13.4 | 18 | 22.2 | 0.7943 |
| Hormone receptor status | |||||
| Positive | 72 | 87.8 | 72 | 88.9 | |
| Negative | 10 | 12.2 | 9 | 11.1 | 0.0037 |
| HER2/neu | |||||
| Positive | 54 | 65.9 | 35 | 43.2 | |
| Negative | 28 | 34.1 | 46 | 56.8 | 0.0037 |
∗All percentage data was calculated excluding the missing data (tumor size: ACP n = 81, no ACP n = 67; grading: ACP n = 75, no ACP n = 81).